Abby Abraham, Vice President, Data Analytics, and RBM for OmniComm Systems, writes about a new survey that highlights gaps in the conversation surrounding the industry’s adoption and implementation of risk-based approaches to monitoring.
Abby Abraham
Advertisement
Articles by Abby Abraham
Case study demonstrates how one global mid-sized sponsor is testing the RBM waters.
Risk-based approaches to monitoring (RBM) have become widely accepted in the clinical trials industry.
This case study examines using centralized manual data review with statistical approaches to compare value and fit.
Advertisement
Latest Updated Articles
Lightship’s Approach to Accessible, Representative, and Impactful Clinical TrialsPublished: February 13th 2025 | Updated: March 4th 2025
Accelerate Inclusive Enrollment and Delivery with LightshipPublished: February 19th 2025 | Updated: February 26th 2025
- Examining the Impact of Exclusionary Behaviors on Team Dynamics
Published: March 24th 2023 | Updated:
Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent AdoptionPublished: April 28th 2021 | Updated:
Sticking to the Plan: Undue Burden Created by Protocol DeviationsPublished: July 26th 2024 | Updated:
Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple MyelomaPublished: January 31st 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
3
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
4
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
